Medical DevicesClick’s Motivista Receives FDA Clearance for Negative Symptoms of Schizop... Click’s Motivista Receives FDA Clearance for Negative Symptoms of Schizop... Read Post »
Clinical TrialsEpcoritamab Plus R-CHOP Cuts DLBCL Progression Risk by 51% Epcoritamab Plus R-CHOP Cuts DLBCL Progression Risk by 51% Read Post »
Health Tidings Mergers & AcquisitionsAlector Signs $1.27 Billion Genentech Deal for Parkinson’s Disease Therap... Alector Signs $1.27 Billion Genentech Deal for Parkinson’s Disease Therap... Read Post »
Clinical TrialsVaxcyte Reports Positive Phase 3 Results for 31-Valent Pneumococcal Vaccine... Vaxcyte Reports Positive Phase 3 Results for 31-Valent Pneumococcal Vaccine... Read Post »
Health Tidings2026 Nobel Prize in Medicine Awarded for Optogenetics 2026 Nobel Prize in Medicine Awarded for Optogenetics Read Post »
Health TidingsCapricor Reports 76% Slower Upper Limb Decline After Deramiocel Switch in H... Capricor Reports 76% Slower Upper Limb Decline After Deramiocel Switch in H... Read Post »
Clinical TrialsBridgeBio’s BBP-418 Shows Cardiac Biomarker Gains in LGMD2I/R9 BridgeBio’s BBP-418 Shows Cardiac Biomarker Gains in LGMD2I/R9 Read Post »
Health Tidings Mergers & AcquisitionsCSL and Alentis Partner to Advance Lixudebart in Kidney and Liver Diseases CSL and Alentis Partner to Advance Lixudebart in Kidney and Liver Diseases Read Post »
Health TidingsBenitec Says FDA Requests Additional Data for BB-301 Pivotal Study in OPMD Benitec Says FDA Requests Additional Data for BB-301 Pivotal Study in OPMD Read Post »
Clinical TrialsRevolution Medicines Begins Phase 3 RASolute 309 Trial of Daraxonrasib and ... Revolution Medicines Begins Phase 3 RASolute 309 Trial of Daraxonrasib and ... Read Post »
Health TidingsSerum Institute of India’s HPV Vaccine CERVAVAC Receives WHO Prequali... Serum Institute of India’s HPV Vaccine CERVAVAC Receives WHO Prequali... Read Post »
Health TidingsStoke Therapeutics Advances Zorevunersen NDA Plan for Dravet Syndrome Stoke Therapeutics Advances Zorevunersen NDA Plan for Dravet Syndrome Read Post »
Clinical TrialsAlterity’s ATH434 Shows 52% Slower Functional Decline in Adjusted Phase 2... Alterity’s ATH434 Shows 52% Slower Functional Decline in Adjusted Phase 2... Read Post »
Health TidingsRezolute Receives FDA Recommendation for Type B Pre-BLA Meeting for Ersodet... Rezolute Receives FDA Recommendation for Type B Pre-BLA Meeting for Ersodet... Read Post »
Mergers & AcquisitionsSernova and Seraxis Close $11.2 Million Financing to Advance BetaNova’s T... Sernova and Seraxis Close $11.2 Million Financing to Advance BetaNova’s T... Read Post »
Health TidingsRilzabrutinib Shows Haemoglobin Responses in Adults with Warm Autoimmune Rilzabrutinib Shows Haemoglobin Responses in Adults with Warm Autoimmune Read Post »
Clinical TrialsLEQSELVI Shows Sustained Hair Regrowth and Consistent Safety Through Two Ye... LEQSELVI Shows Sustained Hair Regrowth and Consistent Safety Through Two Ye... Read Post »
Clinical TrialsRina-S Shows Durable Responses in Platinum-Resistant Ovarian Cancer in RAIN... Rina-S Shows Durable Responses in Platinum-Resistant Ovarian Cancer in RAIN... Read Post »
Health TidingsFDA Extends Novo Nordisk’s Denecimig Review Over Manufacturing Facility R... FDA Extends Novo Nordisk’s Denecimig Review Over Manufacturing Facility R... Read Post »
Clinical TrialsPfizer’s Ritlecitinib Improves Facial and Total-Body Repigmentation in Ph... Pfizer’s Ritlecitinib Improves Facial and Total-Body Repigmentation in Ph... Read Post »
Clinical TrialsBiogen Reports Encouraging 52-Week Results for Litifilimab in Cutaneous Lup... Biogen Reports Encouraging 52-Week Results for Litifilimab in Cutaneous Lup... Read Post »
Health Tidings Mergers & AcquisitionsAbogen and Novartis Partner to Advance mRNA-Encoded T-Cell Engager ABO2203 Abogen and Novartis Partner to Advance mRNA-Encoded T-Cell Engager ABO2203 Read Post »
New Drug ApprovalJaypirca FDA Approval Expands Pirtobrutinib Use in CLL/SLL Jaypirca FDA Approval Expands Pirtobrutinib Use in CLL/SLL Read Post »
Health TidingsFoghorn Therapeutics and Lilly End FHD-909 Development After Phase 1 Review Foghorn Therapeutics and Lilly End FHD-909 Development After Phase 1 Review Read Post »
Clinical TrialsFezolinetant Improves Vasomotor Symptoms and Sleep in Phase 4 OPTION-VMS St... Fezolinetant Improves Vasomotor Symptoms and Sleep in Phase 4 OPTION-VMS St... Read Post »
Health TidingsFILSPARI Achieves 75% Complete Proteinuria Remission in Phase 2 SPARTAN Stu... FILSPARI Achieves 75% Complete Proteinuria Remission in Phase 2 SPARTAN Stu... Read Post »
Clinical TrialsEcopipam Shows Tic Reduction Through 18 Months in Tourette Syndrome Ecopipam Shows Tic Reduction Through 18 Months in Tourette Syndrome Read Post »
Clinical TrialsICONIC-TOTAL Reports 2-Year ICOTYDE Data Showing Sustained Psoriasis Cleara... ICONIC-TOTAL Reports 2-Year ICOTYDE Data Showing Sustained Psoriasis Cleara... Read Post »
Health TidingsAstraZeneca, Daiichi Sankyo and Summit to Test Datroway–Ivonescimab in Ph... AstraZeneca, Daiichi Sankyo and Summit to Test Datroway–Ivonescimab in Ph... Read Post »
Health TidingsRezpegaldesleukin Shows Durable Responses Across Alopecia Areata and Atopic... Rezpegaldesleukin Shows Durable Responses Across Alopecia Areata and Atopic... Read Post »
Health TidingsLundbeck to Present MSA and Parkinson’s Disease Data at MDS 2026 Lundbeck to Present MSA and Parkinson’s Disease Data at MDS 2026 Read Post »
Clinical TrialsRINVOQ Shows Continued Repigmentation in Vitiligo Through Week 76 in Viti-U... RINVOQ Shows Continued Repigmentation in Vitiligo Through Week 76 in Viti-U... Read Post »
Health Tidings Mergers & AcquisitionsItalfarmaco, JCR Sign JR-141 Licensing Deal for Hunter Syndrome Italfarmaco, JCR Sign JR-141 Licensing Deal for Hunter Syndrome Read Post »
Health TidingsREMODEL Trial Identifies Potential Mechanisms of Semaglutide’s Kidney-Pro... REMODEL Trial Identifies Potential Mechanisms of Semaglutide’s Kidney-Pro... Read Post »
Clinical TrialsRegeneron’s Ubamatamab Shows Durable Responses in Advanced LGSOC Regeneron’s Ubamatamab Shows Durable Responses in Advanced LGSOC Read Post »
Health TidingsCullinan Initiates Zipalertinib NDA Under FDA RTOR Program for First-Line E... Cullinan Initiates Zipalertinib NDA Under FDA RTOR Program for First-Line E... Read Post »
Clinical TrialsTrevogrumab Preserved Lean Mass During Semaglutide Weight Loss in Phase 2 C... Trevogrumab Preserved Lean Mass During Semaglutide Weight Loss in Phase 2 C... Read Post »
Clinical TrialsWegovy Reduced Liver Fat in Adults with Obesity in Exploratory STEP-UP Anal... Wegovy Reduced Liver Fat in Adults with Obesity in Exploratory STEP-UP Anal... Read Post »
Health TidingsImmix Reports NXC-201 Shows 89% Complete Response in Amyloidosis Trial Immix Reports NXC-201 Shows 89% Complete Response in Amyloidosis Trial Read Post »
Health TidingsBrogidirsen Five-Year Data Show Maintained Motor Function in DMD Brogidirsen Five-Year Data Show Maintained Motor Function in DMD Read Post »
Health TidingsLUT014 Shows Significant Improvement in EGFR Inhibitor-Induced Acneiform Ra... LUT014 Shows Significant Improvement in EGFR Inhibitor-Induced Acneiform Ra... Read Post »
Clinical TrialsKailera Reports Flexible Ribupatide Injection Sites and Early Weight-Loss S... Kailera Reports Flexible Ribupatide Injection Sites and Early Weight-Loss S... Read Post »
Health TidingsTrichomylin Reports Pain and Opioid-Reduction Signals in UTOPIA-1 Trichomylin Reports Pain and Opioid-Reduction Signals in UTOPIA-1 Read Post »
Health Tidings Mergers & AcquisitionsRegeneron and Sanofi Expand Immunology Deal to $8B With Four Long-Acting An... Regeneron and Sanofi Expand Immunology Deal to $8B With Four Long-Acting An... Read Post »
Clinical TrialsVabysmo Improves Vision and Retinal Anatomy in Real-World VOYAGER Study Vabysmo Improves Vision and Retinal Anatomy in Real-World VOYAGER Study Read Post »
Clinical TrialsPfizer’s Tilrekimig Achieves EASI-75 Across Doses in Phase 2 Atopic D... Pfizer’s Tilrekimig Achieves EASI-75 Across Doses in Phase 2 Atopic D... Read Post »
Clinical TrialsSurvodutide Achieves 13.1% Weight Loss in Phase III Trial Survodutide Achieves 13.1% Weight Loss in Phase III Trial Read Post »
Health TidingsFDA and EMA Grant Orphan Drug Designations to Lemiretprocel for Inherited R... FDA and EMA Grant Orphan Drug Designations to Lemiretprocel for Inherited R... Read Post »
Clinical TrialsGiredestrant Combination Cuts Breast Cancer Progression Risk Up to 62% in e... Giredestrant Combination Cuts Breast Cancer Progression Risk Up to 62% in e... Read Post »
Health TidingsOrforglipron Meets Cardiovascular Safety Goal in Phase 3 ACHIEVE-4 Orforglipron Meets Cardiovascular Safety Goal in Phase 3 ACHIEVE-4 Read Post »
